Lupin Pursues India Approval For Lucentis Biosimilar, COVID-19 Opportunities

Favors Voluntary Licensing

 
• By Vibha Ravi

A bit late to the table, Lupin is exploring voluntary licensing for COVID-19 therapeutics and vaccines from Gilead’s remdesivir to Merck’s molnupiravir. Meanwhile, pricing for a biosimilar to Lucentis, which has been filed for approval in India, will be keenly watched.

Lab Instruments
Lupin Seeks Approval For Lucentis Biosimilar In India As It Expands Product Pipeline • Source: Alamy

More from Strategy

More from Business